Evidence map›Paper›PMID 40746352›Full record

ArticleFrontiers in pediatrics2025

Features of Celiac Disease in children and adolescents with Down syndrome: a single-center experience of annual screening.

Martina Lattuada, Paola Rebora, Chiara Fossati, Alessandra Lazzerotti, Lucia Paolini, Alessandro Cattoni, Roberto Panceri, Maria Grazia Valsecchi, Andrea Biondi, Giovanna Zuin

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martina LattuadaSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Paola ReboraSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Chiara FossatiPediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Alessandra LazzerottiPediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Lucia PaoliniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Alessandro CattoniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Roberto PanceriPediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Maria Grazia ValsecchiSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Andrea BiondiSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Giovanna ZuinPediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Coeliac disease (CD) manifests more frequently in individuals with Down syndrome (DS) and its prevalence varies across different studies. This study aims to assess the prevalence of CD in children with DS and to describe their clinical, serological, and histological features. A secondary aim was to analyze the time needed for the normalization of anti-transglutaminase IgA (TGA-IgA) and anti-endomysium IgA (EMA-IgA) levels in DS compared to non-syndromic (NS) children. Materials and methods: This retrospective monocentric cohort study included patients with DS under 18 years of age, diagnosed with CD between 2005 and 2022. Each DS patient was matched for year of birth and sex with two NS celiac children. Follow-up was 6-, 12- and 24-months post-diagnosis. Results: The prevalence of CD in 770 children with DS was 7.5% (95% CI: 5.8%-9.6%). 57 children with CD and DS were compared with 114 CD NS matched controls (total sample size = 171). DS demonstrated less symptoms than 114 NS CD children (26% vs. 79%, Discussion: This study reinforces the higher prevalence of CD in DS, emphasizing the necessity for routine screening, even in asymptomatic individuals. Despite less symptomatic presentation, patients with DS exhibited elevated antibody levels and severe histological damage. Clinicians should expect a prolonged time for antibody normalization following gluten-free diet in DS, mirroring potential challenges in diet adherence and altered immune responses.

Indexed as

anti-endomysium antibodiesanti-transglutaminase antibodiesCeliac DiseasechildrenDown syndromescreening

Identifiers

PMID40746352
PMCPMC12310593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.